Although CDK4/6i therapy is successful in HR+ breast cancer when combined with hormone therapy, which suppresses c-Myc expression46, CDK4/6i monotherapy often insufficiently blocks cancer progression due to the development of drug resistance. Here, CDK4 is linked to breast carcinoma.